APYX Документы SEC - Apyx Medical Corporation- Годовой отчет, доверенное заявление, проспект эмиссии

Основная статистика

LEI	5299009QZVYUYO082S45
CIK	719135

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Apyx Medical Corporation

SEC Filings (Chronological Order)

На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.

August 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 7, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 7, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati
August 7, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL CORPORAT
August 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 7, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 7, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati
August 7, 2025	EX-99.1	Apyx Medical Corporation Reports Second Quarter 2025 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2025 Financial Results • Successfully launched AYON Body Contouring System™ to key surgeons in critical geographies; plan for commercial launch in September 2025 • Initiated commercial sales of Renuvion® in China with strong clinical interest and completed initial procedures • Based on pre-sales of AYON, the Company increased its total r
June 25, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☒ Definitive Proxy State
June 13, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ☐ Definitive Proxy State
May 30, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 33760 (Address o
May 30, 2025	EX-1.01	2024 Conflict Minerals Report Exhibit 1.01 CONFLICT MINERALS REPORT APYX MEDICAL CORPORATION IN ACCORDANCE WITH RULE 13P-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 This Conflict Minerals Report (“Report”) of Apyx Medical Corporation (“APYX”) for the calendar year ended December 31, 2024 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule requires disclosure of ce
May 13, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 13, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization
May 13, 2025	EX-99.1	Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™ The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body EXHIBIT 99.1 Apyx Medical Corporation Receives FDA Clearance for the AYON Body Contouring System™ The AYON Body Contouring System is the first FDA cleared all-in-one platform for the aesthetic surgical suite Plan to initiate the commercial launch of the AYON Body Contouring System to key opinion leader surgeons in critical geographies during the second half of 2025 Clearwater, Fla. - May 13, 2025
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL CORPORA
May 8, 2025	EX-99.1	Apyx Medical Corporation Reports First Quarter 2025 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2025 Financial Results • Revenue from the Advanced Energy segment increased 6% in Q1 2025 compared with the same period last year • U.S. single use handpiece revenue grew 14% in Q1 2025 compared with the same period last year • Preparing for a planned launch of the AYON™ Body Contouring System in the second half of 2025, pending U.S. FDA
May 8, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 8, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization)
April 29, 2025	EX-99.1	APYX MEDICAL CORPORATION ANNOUNCES TWO PEER-REVIEWED PUBLICATIONS ON THE USE OF RENUVION IN ABDOMINAL BODY CONTOURING PROCEDURES Two studies report favorable clinical outcomes and safety data for Renuvion® when used during procedures that include lip EXHIBIT 99.1 APYX MEDICAL CORPORATION ANNOUNCES TWO PEER-REVIEWED PUBLICATIONS ON THE USE OF RENUVION IN ABDOMINAL BODY CONTOURING PROCEDURES Two studies report favorable clinical outcomes and safety data for Renuvion® when used during procedures that include lipoabdominoplasty for the treatment of loose and lax skin Rapid weight loss due to GLP-1 drugs expected to drive growth in patients seeking
April 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 29, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 29, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati
March 13, 2025	EX-21.1	List of Subsidiaries Exhibit 21.1 APYX MEDICAL CORPORATION SUBSIDIARIES OF REGISTRANT SUBSIDIARY NAME STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Apyx Bulgaria EOOD Bulgaria Apyx China Holding Corp. Delaware Apyx SY Medical Devices (NINGBO) Co., LTD. China
March 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 13, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati
March 13, 2025	EX-99.1	Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year 2024 Financial Results • The number of single-use handpiece units shipped in Q4 2024 exceeded expectations, increasing 5% overall and 20% in the U.S. compared to the same period last year • Submitted a 510(k) premarket notification to the U.S. FDA for the AYON™ Body Contouring System ahead of schedule and preparing for a pl
March 13, 2025	EX-14	Insider Trading Policy, included in Exhibit 14 EXHIBIT 14 Code of Business Conduct and Ethics (excerpt from Employee Handbook March 2025) INTRODUCTION The Board of Directors of Apyx Medical Corporation (“Apyx” or the “Company”) has adopted this Code of Business Conduct and Ethics (the "Code") in order to: ● promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest; ● promote full, fair, accu
March 13, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX ME
February 6, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 31, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza
February 6, 2025	EX-10.1	Employment Agreement, effective as of January 28, 2025, by and between the Company and Shawn Roman. Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, effective as of January 28, 2025 (the “Effective Date”), is hereby entered into by and between Apyx Medical Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”) and Shawn Roman ( “Executive”). WITNESSETH: WHEREAS, the Company agrees to employ Executive and Executive agrees to be employ
January 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 13, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 13, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza
January 13, 2025	EX-99.1	Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results EXHIBIT 99.1 Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2024 Revenue Results Advanced Energy revenue increase by more than 25% quarter-over-quarter in Q4 2024 Clearwater, Fla. — January 13, 2025 - Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and
January 6, 2025	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 6, 2025 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizat
January 6, 2025	EX-99.1	Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™ EXHIBIT 99.1 Apyx Medical Corporation Submits 510(k) Premarket Notification to the U.S. Food and Drug Administration for the AYON Body Contouring System™ Focusing on advancing body contouring by providing the first all-in-one platform for the surgical suite Clearwater, Fla. — January 6, 2025 - Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietar
November 8, 2024	EX-10.2	Securities Purchase Agreement, dated November 7, 2024. Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 7, 2024, between Apyx Medical Corporation, a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi
November 8, 2024	EX-10.1	Amendment No.1 to Credit Agreement and Guaranty, dated November 7, 2024 Exhibit 10.1 Execution Version AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY This AMENDMENT NO. 1 TO CREDIT AGREEMENT AND GUARANTY, dated as of November 7, 2024 (this “Amendment”), is among Apyx Medical Corporation, a Delaware corporation (the “Borrower”), the Subsidiary Guarantors party hereto, the Lenders party hereto and Perceptive Credit Holdings IV, LP, as administrative agent for the Lend
November 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL COR
November 8, 2024	EX-99.2	Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering Exhibit 99.2 Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering CLEARWATER, FL — November 8, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nant
November 8, 2024	424B5	APYX MEDICAL CORPORATION 3,000,000 Shares of Common Stock 2,934,690 Pre-Funded Warrants to Purchase up to 2,934,690 Shares of Common Stock 2,934,690 Shares of Common Stock underlying the Pre-Funded Warrants Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-268532 Prospectus Supplement (To Prospectus dated December 2, 2022) APYX MEDICAL CORPORATION 3,000,000 Shares of Common Stock 2,934,690 Pre-Funded Warrants to Purchase up to 2,934,690 Shares of Common Stock 2,934,690 Shares of Common Stock underlying the Pre-Funded Warrants We are offering 3,000,000 shares of our common stock, par val
November 8, 2024	EX-99.1	Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook ● Strengthened balance sheet with a common stock registered direct offering with gross pro EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook ● Strengthened balance sheet with a common stock registered direct offering with gross proceeds of approximately $7.0 million; and amended revenue covenants for the Company’s credit agreement with Perceptive ● Announces cost sa
November 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 4, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 4, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza
November 8, 2024	EX-4.1	Form of Pre-Funded Warrant. Exhibit 4.1 PRE-FUNDED COMMON STOCK PURCHASE WARRANT APYX MEDICAL CORPORATION Warrant Shares: Issue Date: November [●], 2024 Initial Exercise Date: November [●], 2024 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set
October 31, 2024	EX-99.1	Joint Filing Agreement EX-99.1 2 ex991to13g14118002103124.htm Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated October 31, 2024 with respect to the Common Stock, $0.001 par value, of Apyx Medical Corporation and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with
October 31, 2024	SC 13G	APYX / Apyx Medical Corporation / Archon Capital Management LLC - SCHEDULE 13G Passive Investment SC 13G 1 sc13g1411800210312024.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Apyx Medical Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of
August 12, 2024	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 8, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati
August 8, 2024	EX-99.1	Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook CLEARWATER, FL — August 8, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported financial results for its second q
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 8, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL CORPORAT
June 25, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the app UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ý Definitive Proxy State
May 31, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 33760 (Address o
May 31, 2024	EX-1.01	Conflict Minerals Report Exhibit 1.01 CONFLICT MINERALS REPORT APYX MEDICAL CORPORATION IN ACCORDANCE WITH RULE 13P-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 This Conflict Minerals Report (“Report”) of Apyx Medical Corporation (“APYX”) for the calendar year ended December 31, 2023 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule requires disclosure of ce
May 9, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 7, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization)
May 9, 2024	EX-99.1	Apyx Medical Corporation Reports First Quarter 2024 Financial Results; Reaffirms Full Year 2024 Financial Outlook EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2024 Financial Results; Reaffirms Full Year 2024 Financial Outlook CLEARWATER, FL — May 9, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended
May 9, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL CORPORA
May 9, 2024	EX-99.1	Apyx Medical Corporation Announces Board Leadership Transition Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman EXHIBIT 99.1 Apyx Medical Corporation Announces Board Leadership Transition Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman CLEARWATER, FL — May 9, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma a
May 9, 2024	SC 13D/A	APYX / Apyx Medical Corporation / Vizirgianakis Stavros G. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Apyx Medical Corporation (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 03837C106 (CUSIP Number) Stavros G. Vizirgianakis c/o Amy E. Culbert, Esq. Fox Rothschild LLP City Center 33 South Sixth Street, Suite 3600 Minneapoli
May 9, 2024	EX-10.1	Letter Agreement, dated May 7, 2024, between Apyx Medical Corporation and Stavros G. Vizirgianakis Execution Version\ Exhibit 10.1 APYX MEDICAL CORPORATION. 5115 Ulmerton Road Clearwater, Florida 33760 May 7, 2024 Via Email Mr. Stavros G. Vizirgianakis 99 Boulevard du Jardin Exotique, Monaco 98000 Dear Mr. Vizirgianakis: The Board of Directors (the “Board”) of Apyx Medical Corporation (the “Company”) has considered appointing you as a director (in such capacity, you are referred to herein as th
May 9, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 9, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organization)
April 5, 2024	SC 13D	APYX / Apyx Medical Corporation / Archon Capital Management LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Apyx Medical Corporation (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 03837C106 (CUSIP Number) MR. Constantinos J. Chr
April 5, 2024	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 ex991to13d00322001040424.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par va
April 1, 2024	SC 13D	APYX / Apyx Medical Corporation / Vizirgianakis Stavros G. - SC 13D Activist Investment SC 13D 1 ef20025615sc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Apyx Medical Corporation (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 03837C106 (CUSIP Number) Stavros G. Vizirgianakis c/o Amy E. Culbert, Esq. Fox Rothschild LLP City Center 33 South
March 25, 2024	SC 13G/A	APYX / Apyx Medical Corporation / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) March 22, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropria
March 21, 2024	EX-21.1	List of Subsidiaries APYX MEDICAL CORPORATION SUBSIDIARIES OF REGISTRANT SUBSIDIARY NAME STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Apyx Bulgaria EOOD Bulgaria Apyx China Holding Corp. Delaware Apyx SY Medical Devices (NINGBO) Co., LTD. China
March 21, 2024	EX-97.1	Apyx Medical Corporation Clawback Policy, effective October 2, 2023 EXHIBIT 97.1 EXECUTIVE COMPENSATION CLAWBACK POLICY 1.Introduction The Board of Directors (the “Board”) of Apyx Medical Corporation (the “Company”) and its wholly owned subsidiaries have adopted this policy (this “Policy”) to provide for the recovery or “clawback” of erroneously awarded incentive-based compensation from certain executive officers in accordance with Section 10D of the Securities Ex
March 21, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 21, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizati
March 21, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL CORPORATION
March 21, 2024	EX-99.1	Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook Advanced Energy Sales increased 15% year-over-year and 23% quarter-over-quarter in the fourth quarter; increased 18% yea EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook Advanced Energy Sales increased 15% year-over-year and 23% quarter-over-quarter in the fourth quarter; increased 18% year-over-year in 2023 CLEARWATER, FL — March 21, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufac
February 21, 2024	EX-99.1	Presentation hosted by Dr. Michael Kluska to feature the results of a retrospective clinical study comparing the use of Renuvion to a competing technology when used in conjunction with liposuction or body contouring, demonstrating significantly fewer EXHIBIT 99.1 Apyx Medical Corporation Announces Renuvion to be Featured in Educational Sessions at the American Academy of Cosmetic Surgery (AACS) Scientific Meeting Presentation hosted by Dr. Michael Kluska to feature the results of a retrospective clinical study comparing the use of Renuvion to a competing technology when used in conjunction with liposuction or body contouring, demonstrating sig
February 21, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 21, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiz
February 14, 2024	SC 13G/A	APYX / Apyx Medical Corporation / RTW INVESTMENTS, LP - APYX MEDICAL CORPORATION Passive Investment SC 13G/A 1 p24-0394sc13ga.htm APYX MEDICAL CORPORATION SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Apyx Medical Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement
February 14, 2024	SC 13G/A	APYX / Apyx Medical Corporation / Divisadero Street Capital Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 13, 2024	SC 13G/A	APYX / Apyx Medical Corporation / Archon Capital Management LLC Passive Investment SC 13G/A 1 d1096421913g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b
February 7, 2024	SC 13G/A	APYX / Apyx Medical Corporation / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp
February 2, 2024	SC 13G/A	APYX / Apyx Medical Corporation / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment SC 13G/A 1 apyxa320224.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Apyx Medical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 03837c106 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropria
January 22, 2024	EX-99.1	Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body Analysis of data from 483 patients with a total of 1,184 body areas treated found the use of EXHIBIT 99.1 Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body Analysis of data from 483 patients with a total of 1,184 body areas treated found the use of Renuvion for subcutaneous soft tissue contraction following liposuction demonstrated no new or increased risks for any area of the body,
January 22, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 22, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 22, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza
January 8, 2024	EX-99.1	Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results EXHIBIT 99.1 Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results CLEARWATER, FL — January 8, 2024 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended Decem
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 8, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 8, 2024 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organizat
November 28, 2023	EX-99.1	Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer Apyx Medical Corporation Appoints Matthew Hill as Chief Financial Officer CLEARWATER, FL — November 28, 2023 - Apyx Medical Corporation (Nasdaq:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023.
November 28, 2023	EX-10.1	Employment Agreement, effective as of December 4, 2023, by and between the Company and Matthew Hill. EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT, effective as of December 4, 2023 (the “Effective Date”), is hereby entered into by and between Apyx Medical Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company”) and Matthew Hill (the “Executive”).
November 28, 2023	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 21, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiz
November 16, 2023	EX-99.2	Roman Stock Option Agreement
November 16, 2023	EX-99.1	Hornsby Stock Option Agreement
November 16, 2023	S-8	As filed with the Securities and Exchange Commission on November 16, 2023 As filed with the Securities and Exchange Commission on November 16, 2023 Registration No.
November 16, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) APYX MEDICAL CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.
November 16, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) APYX MEDICAL CORPORATION (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, par value $0.
November 16, 2023	S-8	As filed with the Securities and Exchange Commission on November 16, 2023 As filed with the Securities and Exchange Commission on November 16, 2023 Registration No.
November 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 9, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 9, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza
November 9, 2023	EX-4.1	Warrant to Purchase Stock, dated Exhibit 4.1 WARRANT CERTIFICATE THIS WARRANT certificate AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT certificate HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR QUALIFIED UNDER ANY STATE OR FOREIGN SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED OR ASSIGNED UNLESS (I) A REGISTRATION STATEMENT COVERING SUC
November 9, 2023	EX-99.1	Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors New facility includes senior, secured term loans of up to $45 million Exhibit 99.1 Apyx Medical Corporation Announces New Debt Facility with Perceptive Advisors New facility includes senior, secured term loans of up to $45 million CLEARWATER, FL — November 9, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that the Company and
November 9, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-31885 APYX MEDICAL COR
November 9, 2023	EX-99.1	Apyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook Advanced Energy Sales increased 39% year-over-year in Q3 EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook Advanced Energy Sales increased 39% year-over-year in Q3 CLEARWATER, FL — November 9, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reporte
November 9, 2023	EX-10.1	and Guaranty Agreement, dated Exhibit 10.1 CREDIT AGREEMENT AND GUARANTY dated as of November 8, 2023 between APYX MEDICAL CORPORATION as the Borrower, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Subsidiary Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO, as the Lenders, and PERCEPTIVE CREDIT HOLDINGS IV, LP, as the Initial Lender and Administrative Agent U.S. $45,000,000 Table of Contents Page SECT
November 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 9, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-31885 11-2644611 (State or other jurisdiction of incorporation or organiza
November 9, 2023	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 8, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 00-31885 11-2644611 (State or other jurisdiction of incorporation or organizat
August 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 10, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 10, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio
August 14, 2023	SC 13G	APYX / Apyx Medical Corp / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) August 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh
August 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATIO
August 10, 2023	EX-99.1	Apyx Medical Corporation Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Outlook Advanced Energy Sales increased 40% year-over-year in Q2 EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2023 Financial Results and Reaffirms Full Year 2023 Financial Outlook Advanced Energy Sales increased 40% year-over-year in Q2 CLEARWATER, FL — August 10, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today repor
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 10, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 10, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio
June 23, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the app UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ý Definitive Proxy State
June 13, 2023	SC 13G/A	APYX / Apyx Medical Corp / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) June 6, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
May 31, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 10577 (Address of
May 31, 2023	EX-1.01	Conflict Minerals Report a2022conflictxmineralsx Exhibit 1.01 CONFLICT MINERALS REPORT APYX MEDICAL CORPORATION IN ACCORDANCE WITH RULE 13P-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 This Conflict Minerals Report (“Report”) of Apyx Medical Corporation (“APYX”) for the calendar year ended December 31, 2022 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule r
May 19, 2023	SC 13G	APYX / Apyx Medical Corp / Divisadero Street Capital Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Apyx Medical Corporation (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03837C106 (CUSIP Number) May 18, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant
May 12, 2023	SC 13G	APYX / Apyx Medical Corp / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03837C106 (CUSIP Number) May 11, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 11, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 11, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization)
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATI
May 11, 2023	EX-99.1	Apyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Financial Outlook CLEARWATER, FL — May 11, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its first quarter ended March 31, 202
April 18, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 13, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
April 18, 2023	EX-10.1	First Amendment to Purchase and Sale Agreement, dated April 12, 2023 psaamendment First Amendment to Apyx – VK PSA 1 ACTIVE 686727528v2 First Amendment to Purchase and Sale Agreement (Inspection Period, Closing Extension) BY THIS FIRST AMENDMENT TO PURCHASE AND SALE AGREEMENT (INSPECTION PERIOD, CLOSING DATE) (this “First Amendment”), is made effective as of the 12th day of April 2023, by and between VK ACQUISTIONS VI, LLC, a Delaware limited liability company (“Purchaser”), and APYX MEDICAL CORPORATION, a Delaware corporation (“Seller”), in consideration of the premises and the mutual covenants set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, agree as follows: 1.
March 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 16, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 16, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
March 16, 2023	EX-21.1	List of Subsidiaries APYX MEDICAL CORPORATION SUBSIDIARIES OF REGISTRANT SUBSIDIARY NAME STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Apyx Bulgaria EOOD Bulgaria Apyx China Holding Corp. Delaware Apyx SY Medical Devices (NINGBO) Co., LTD. China
March 16, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATION (E
March 16, 2023	EX-99.1	Apyx Medical Corporation Reports Fourth Quarter and Full Year 2022 Financial Results; Introduces Full Year 2023 Financial Outlook EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year 2022 Financial Results; Introduces Full Year 2023 Financial Outlook CLEARWATER, FL — March 16, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter a
March 15, 2023	EX-10.1	Purchase and Sale Agreement, dated March 14, 2023 EXECUTION VERSION PURCHASE AND SALE AGREEMENT THIS PURCHASE AND SALE AGREEMENT (the “Agreement”) is made and entered into as of this 13th day of March, 2023 (the “Effective Date”), by and between Apyx Medical Corporation, a Delaware corporation (the “Seller”) and VK Acquisitions VI, LLC, a Delaware limited liability company (the “Purchaser”).
March 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 14, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 14, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
March 15, 2023	EX-10.2	Form of Single Tenant Industrial Building Lease SINGLE TENANT INDUSTRIAL BUILDING LEASE Between VK , LLC, Landlord, and APYX MEDICAL CORPORATION, Tenant Dated: , 2023 5115 ULMERTON ROAD, CLEARWATER, FLORIDA 33760 TABLE OF CONTENTS Article 1 BASIC LEASE PROVISIONS 1 2 GRANT OF LEASE; TERM; POSSESSION 3 3 BASE RENT 3 4 IMPOSITIONS 4 5 USE OF PREMISES 5 6 UTILITIES AND SERVICES 5 7 CONDITION OF PREMISES; COMPLIANCE WITH LEGAL REQUIREMENTS 6 8 RETU
February 24, 2023	EX-99.1	Apyx Medical Corporation Announces New Five-Year Credit Agreement with MidCap Financial Facility includes a senior, secured term loan of up to $25 million and a revolving line of credit of up to $10 million EXHIBIT 99.1 Apyx Medical Corporation Announces New Five-Year Credit Agreement with MidCap Financial Facility includes a senior, secured term loan of up to $25 million and a revolving line of credit of up to $10 million CLEARWATER, FL — February 21, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed
February 24, 2023	EX-10.3	Warrant to Purchase Stock, dated February 17, 2023 Exhibit 10.3 Execution Version THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AND PURSUANT TO THE PROVISIONS OF ARTICLE 5 BELOW, MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND APPLICABLE STATE S
February 24, 2023	EX-10.2	Fee Letter, dated February 17, 2023 Exhibit 10.2 Execution Version c/o MidCap Financial Services, LLC, as servicer 7255 Woodmont Avenue, Suite 300 Bethesda, Maryland 20814 www.midcapfinancial.com February 17, 2023 Apyx Medical Corporation 5115 Ulmerton Rd. Clearwater, FL 33760 Attn: Tara Semb Re: Credit, Security and Guaranty Agreement with Apyx Medical Corporation and Apyx China Holding Corp. Ladies and Gentlemen: This fee letter (
February 24, 2023	EX-10.1	Credit, Security and Guaranty Agreement, dated February 17, 2023 Exhibit 10.1 Execution Version CREDIT, SECURITY AND GUARANTY AGREEMENT dated as of February 17, 2023 by and among APYX MEDICAL CORPORATION, as Borrower and any additional borrower that hereafter becomes party hereto, each as Borrower, and collectively as Borrowers, and APYX CHINA HOLDING CORP. as Guarantor and any additional guarantor that hereafter becomes party hereto, each as Guarantor, and col
February 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 17, 2023 Date of Report (date of earliest event reported) APYX MEDICAL COR UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 February 17, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizat
February 13, 2023	SC 13G/A	APYX / Apyx Medical Corp / Archon Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 11, 2023	SC 13G/A	APYX / Apyx Medical Corp / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Apyx Medical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 03837c106 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
January 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 10, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 10, 2023 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati
January 10, 2023	EX-99.1	Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results EXHIBIT 99.1 Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2022 Revenue Results CLEARWATER, FL — January 10, 2023 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended Dece
December 2, 2022	S-3/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delawa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 11-2644611 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater,
November 30, 2022	CORRESP	November 30, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. St., N.E. Washington, D.C. 20549 Re: Request for Acceleration of Effectiveness of Registration Statement on Form S-3 (File No. 333-268 November 30, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F.
November 22, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 2 filingfeetable.htm EX-FILING FEES Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Apyx Medical Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggreg
November 22, 2022	S-3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT THE SECURITIES ACT OF 1933 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 11-2644611 (State or other jur UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 11-2644611 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, FL 33760 (727) 384-2323 (Address
November 22, 2022	EX-1.2	Equity Distribution Agreement, dated as of November 22, 2022, by and between the Registrant and Piper Sandler & Co. APYX MEDICAL CORPORATION EQUITY DISTRIBUTION AGREEMENT November 22, 2022 PIPER SANDLER & CO.
November 22, 2022	EX-4.1	Form of Indenture Exhibit 4.1 APYX MEDICAL CORPORATION INDENTURE Dated as of , 20 ii TABLE OF CONTENTS Page No. ARTICLE I DEFINITIONS 1 Section 1.01. Definitions 2 ARTICLE II FORMS OF SECURITIES 9 Section 2.01. Terms of the Securities 9 Section 2.02. Form of Trustee?s Certificate of Authentication 9 ARTICLE III THE DEBT SECURITIES 10 Section 3.01. Amount; Issuable in Series 10 Section 3.02. Denominations 13 Section
November 21, 2022	SC 13G/A	APYX / Apyx Medical Corp / Archon Capital Management LLC Passive Investment apUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
November 10, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPO
November 10, 2022	EX-99.1	Apyx Medical Corporation Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook CLEARWATER, FL — November 10, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its third quarter ended Septembe
November 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 10, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizat
August 17, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 11, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio
August 11, 2022	EX-99.1	Apyx Medical Corporation Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook CLEARWATER, FL ? August 11, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion?, today reported financial results for its second quarter ended June 30,
August 11, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATIO
August 11, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 11, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio
July 18, 2022	EX-99.1	1 Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® to Improve Appearance of Lax (Loose) Skin CLEARWATER, FL — July 18, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), the manufacturer of a proprietary hel 1 Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion? to Improve Appearance of Lax (Loose) Skin CLEARWATER, FL ? July 18, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion?, today announced it has received 510(k) clearance from the U.
July 18, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 July 18, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization)
June 24, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the app UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy State
June 13, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(D) of The Securities Exchange Act of 1934 June 7, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization)
May 27, 2022	EX-1.01	2021 Conflict Minerals Report EX-1.01 2 conflictmineralsxreport.htm EX-1.01 Exhibit 1.01 CONFLICT MINERALS REPORT APYX MEDICAL CORPORATION IN ACCORDANCE WITH RULE 13P-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 This Conflict Minerals Report (“Report”) of Apyx Medical Corporation (“APYX”) for the calendar year ended December 31, 2021 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (t
May 27, 2022	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 10577 (Address of
May 26, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 26, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization)
May 26, 2022	EX-99.1	1 Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion® Cosmetic Technology in Dermal Resurfacing Procedures CLEARWATER, FL — May 26, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices 1 Apyx Medical Corporation Receives FDA 510(k) Clearance for the Use of Renuvion? Cosmetic Technology in Dermal Resurfacing Procedures CLEARWATER, FL ? May 26, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? and J- Plasma? in surgical markets, today announced it has received 510(k) clearance from the U.
May 12, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATI
May 12, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 May 12, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization)
May 12, 2022	EX-99.1	Apyx Medical Corporation Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook Advanced Energy sales increased 41% year-over-year in Q1 EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2022 Financial Results and Updates Full Year 2022 Financial Outlook Advanced Energy sales increased 41% year-over-year in Q1 CLEARWATER, FL ? May 12, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? and J-Pla
April 4, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 April 4, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization)
April 4, 2022	EX-99.1	Apyx Medical Corporation Announces FDA 510(k) Submission with Clinical Study Support for the Use of the Renuvion® APR Handpiece for Aesthetic Procedures to Improve Appearance of Lax Skin CLEARWATER, FL — April 4, 2022 - Apyx Medical Corporation (NASD Apyx Medical Corporation Announces FDA 510(k) Submission with Clinical Study Support for the Use of the Renuvion? APR Handpiece for Aesthetic Procedures to Improve Appearance of Lax Skin CLEARWATER, FL ? April 4, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmetic surgery market and J-Plasma? in the hospital surgical market, today announced it has submitted a 510(k) premarket notification (?510(k) submission?) to the U.
March 21, 2022	8-K/A	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 1, 2019 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati
March 17, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATION (E
March 17, 2022	EX-21.1	List of Subsidiaries APYX MEDICAL CORPORATION SUBSIDIARIES OF REGISTRANT SUBSIDIARY NAME STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Apyx Bulgaria EOOD Bulgaria Apyx China Holding Corp. Delaware
March 17, 2022	EX-99.1	Apyx Medical Corporation Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Outlook Advanced Energy Sales increased 52% year-over-year in Q4; up 94% year-over-year in 2021 EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year 2021 Financial Results; Introduces Full Year 2022 Financial Outlook Advanced Energy Sales increased 52% year-over-year in Q4; up 94% year-over-year in 2021 CLEARWATER, FL ? March 17, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Tech
March 17, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 17, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
March 14, 2022	EX-99.1	Apyx Medical Corporation Notified of Pending FDA Medical Device Safety Communication Related to its Advanced Energy Products CLEARWATER, FL — March 14, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supp Apyx Medical Corporation Notified of Pending FDA Medical Device Safety Communication Related to its Advanced Energy Products CLEARWATER, FL ? March 14, 2022 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmetic surgery market and J-Plasma? in the hospital surgical market, today announced it has been notified by the U.
March 14, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 March 14, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
February 14, 2022	SC 13G/A	APYX / Apyx Medical Corp / RTW INVESTMENTS, LP - APYX MEDICAL CORPORATION Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Apyx Medical Corporation (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2021 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursu
February 14, 2022	SC 13G/A	APYX / Apyx Medical Corp / Archon Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 20, 2022	SC 13G/A	APYX / Apyx Medical Corp / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Apyx Medical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 03837c106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
January 10, 2022	EX-99.1	1 Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Results Advanced Energy Sales of approximately $14.7 to $15.0 million in Q4, up 49% to 52% year-over-year CLEARWATER, FL — JANUARY 10, 2022 - Apyx Medical Corpor 1 Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Results Advanced Energy Sales of approximately $14.
January 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 10, 2022 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati
November 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPO
November 12, 2021	EX-99.1	Apyx Medical Corporation Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 88% year-over-year in Q3 EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 88% year-over-year in Q3 CLEARWATER, FL ? November 11, 2021 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmeti
November 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 November 11, 2021 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizat
August 30, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 24, 2021 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio
August 30, 2021	EX-99.1	Apyx Medical Corporation Announces Appointment of Wendy Levine to the Company’s Board of Directors CLEARWATER, FL — August 30, 2021 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Apyx Medical Corporation Announces Appointment of Wendy Levine to the Company?s Board of Directors CLEARWATER, FL ? August 30, 2021 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmetic surgery market and J-Plasma? in the hospital surgical market, announced today that the Company has appointed Wendy Levine to the Board of Directors, effective August 25, 2021.
August 26, 2021	SC 13G	APYX / Apyx Medical Corp / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Apyx Medical Corp. (Name of Issuer) Common Stock (Title of Class of Securities) 03837c106 (CUSIP Number) August 13, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Ru
August 18, 2021	S-8	As filed with the Securities and Exchange Commission on August 18, 2021 As filed with the Securities and Exchange Commission on August 18, 2021 Registration No.
August 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 August 12, 2021 Date of Report (date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio
August 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATIO
August 12, 2021	EX-99.1	Apyx Medical Corporation Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 248% year-over-year in Q2 EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 248% year-over-year in Q2 CLEARWATER, FL ? August 12, 2021 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmeti
August 9, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 6, 2021 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
July 6, 2021	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Amendment No. 1 Filed by the Registrant ý Filed by a party other than the Registrant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Amendment No. 1 Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) o Defini
June 25, 2021	DEF 14A	4.1 Apyx Medical Corporation 20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a?6(e)(2)) ? Definitive Proxy State
May 26, 2021	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 10577 (Address of
May 26, 2021	EX-1.01	Youâve Exceeded the SECâs Traffic Limit U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains
May 12, 2021	EX-99.1	Apyx Medical Corporation Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 92% year-over-year in Q1 EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2021 Financial Results and Updates Full Year 2021 Outlook Advanced Energy Sales increased 92% year-over-year in Q1 CLEARWATER, FL ? MAY 12, 2021 - Apyx Medical Corporation (NASDAQ:APYX) (the ?Company?), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion? in the cosmetic sur
May 12, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ☐ TRANSITION REPORT PURSUANT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATI
May 12, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 12, 2021 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization)
March 31, 2021	10-K	Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATION (E
March 31, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 31, 2021 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
March 31, 2021	EX-99.1	Apyx Medical Corporation Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Outlook Advanced Energy Sales increased 44% year-over-year in Q4 EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Outlook Advanced Energy Sales increased 44% year-over-year in Q4 CLEARWATER, FL — MARCH 31, 2021 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Re
March 30, 2021	8-K	Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 25, 2021 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
February 16, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 12, 2021	EX-1	Joint Filing Statement Pursuant to Rule 13d-1(k)(1) EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No. 4 under the Securities Exchange Act of 1934, as amended, with respect to the common stock, $0.001 par value, of Apyx Medical Corporation. beneficially owned by them, together with any or all amendments thereto, when and if appropria
February 12, 2021	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Apyx Medical Corporation (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number) Decem UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 13, 2021	EX-99.1	Apyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2020 Revenue Results Advanced Energy Sales of approximately $9.5 to $9.8 million in Q4, up 39% to 43% year-over-year Apyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2020 Revenue Results Advanced Energy Sales of approximately $9.
January 13, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 January 13, 2021 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati
November 12, 2020	8-K	Entry into a Material Definitive Agreement - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 5, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati
November 9, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPO
November 9, 2020	EX-99.1	Apyx Medical Corporation Reports Third Quarter 2020 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter 2020 Financial Results CLEARWATER, FL — NOVEMBER 9, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial resu
November 9, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 9, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati
September 18, 2020	EX-10.1	Charles D. Goodwin II Amended and Restated Employment Agreement amendedrestatedgoodwinem EXECUTION VERSION AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), effective as of September 17, 2020 (the “Effective Date”), by and between Apyx Medical Corporation, a corporation organized and existing under the laws of the State of Delaware (hereinafter referred to as the “Company") and Charles D.
September 18, 2020	EX-10.3	Todd Hornsby Amended and Restated Employment Agreement toddhornsbyagreement EXECUTION VERSION AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”), effective as of September 17, 2020 (the “Effective Date”), by and between Apyx Medical Corporation, a corporation organized and existing under the laws of the State of Delaware (hereinafter referred to as the “Company") and Todd Hornsby (hereinafter referred to as the “Executive").
September 18, 2020	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 September 16, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organiza
September 18, 2020	EX-10.2	Tara Harris Semb Amended and Restated Employment Agreement sembemploymentagreement EXECUTION VERSION AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT, effective as of September 16, 2020 (the “Effective Date”), is hereby entered into by and between Apyx Medical Corporation, a corporation organized and existing under the laws of the State of Delaware (the “Company") and Tara Harris Semb (the “Executive").
August 21, 2020	EX-16.1	Letter from BDO USA, LLP, dated August 20, 2020 EX-16.1 2 bdoletter.htm EXHIBIT 16.1 Tel: 813-321-6869 501 E Kennedy Blvd, Suite 910 Fax: 813-448-1886 Tampa, FL 33602 www.bdo.com August 20, 2020 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 We have been furnished with a copy of the response to Item 4.01 of Form 8-K for the event that occurred on August 17, 2020, to be filed by our former client, Apyx Medical Corp.
August 21, 2020	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 17, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its Charter) Delaware 012183 11-2644611 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
August 10, 2020	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 6, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
August 10, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 August 10, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizatio
August 10, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATIO
August 10, 2020	EX-99.1	Apyx Medical Corporation Reports Second Quarter 2020 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter 2020 Financial Results CLEARWATER, FL — AUGUST 10, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial resu
June 30, 2020	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Amendment No. 1 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) o Defini
June 26, 2020	DEF 14A	- DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ý Definitive Proxy State
June 1, 2020	SD	- SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 10577 (Address of
June 1, 2020	EX-1.01	2019 Conflict Minerals Report exhibit101 Exhibit 1.01 CONFLICT MINERALS REPORT APYX MEDICAL CORPORATION IN ACCORDANCE WITH RULE 13P-1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 This Conflict Minerals Report (“Report”) of Apyx Medical Corporation (“APYX”) for the calendar year ended December 31, 2019 is presented to comply with Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). Numerous terms in this
May 11, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 May 11, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization)
May 11, 2020	EX-99.1	Apyx Medical Corporation Reports First Quarter 2020 Financial Results EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2020 Financial Results CLEARWATER, FL — MAY 11, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results
May 11, 2020	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATI
May 8, 2020	10-Q/A	Quarterly Report - 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX
May 8, 2020	10-Q/A	Quarterly Report - 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A Amendment No. 1 ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183
March 31, 2020	EX-14.1	Code of Ethics apyxmedicalcodeofbusines CODE OF BUSINESS CONDUCT AND ETHICS (excerpt from EMPLOYEE HANDBOOK) DECEMBER 2019 Code of Business Conduct and Ethics INTRODUCTION The Board of Directors of Apyx Medical Corporation (“Apyx” or the “Company”) has adopted this Code of Business Conduct and Ethics (the "Code") in order to:  promote honest and ethical conduct, including the ethical handling of actual or appar
March 31, 2020	EX-4.2	Description of the Registrant’s Securities apyxdescriptionofsecurit DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following description of the common stock of Apyx Medical Corporation (referred to as “the Company”, “we”, “us” and “our” unless specified otherwise) is based upon relevant provisions of the Company’s Certificate of Incorporation, as amended (the “Certificate of Incorporation”), the Company’s Bylaws (the “Bylaws”) and applicable provisions of law.
March 31, 2020	EX-21.1	List of Subsidiaries EXHIBIT 21.1 APYX MEDICAL CORPORATION SUBSIDIARIES OF REGISTRANT SUBSIDIARY NAME STATE OR OTHER JURISDICTION OF INCORPORATION OR ORGANIZATION Bovie Holdings, Inc. Delaware BVX Holdings LLC Delaware Apyx Bulgaria EOOD Bulgaria Apyx China Holding Corp. Delaware
March 31, 2020	10-K	BVX / Bovie Medical Corp. 10-K - Annual Report - 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATION (E
March 19, 2020	8-K/A	Financial Statements and Exhibits, Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 16, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati
March 19, 2020	EX-7.1	Frazier & Deeter, LLC letter dated March 16, 2020 a20200316form8kletterapy March 16, 2020 Securities and Exchange Commission 100 F Street, N.
March 19, 2020	EX-99.1	Apyx Medical Corporation Reports Fourth Quarter and Full Year of 2019 Preliminary Unaudited Financial Results and Introduces First Quarter of Fiscal Year 2020 Financial Outlook Advanced Energy Sales increase 58% year-over-year in Q4 and increase 73% EX-99.1 3 a2019q4apyxex991earningsre.htm EXHIBIT 99.1 EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year of 2019 Preliminary Unaudited Financial Results and Introduces First Quarter of Fiscal Year 2020 Financial Outlook Advanced Energy Sales increase 58% year-over-year in Q4 and increase 73% year-over-year in FY'19 CLEARWATER, FL — MARCH 16, 2020 - Apyx Medical Corporation
March 19, 2020	EX-99.2	Apyx Medical Corporation to Restate Previously Issued Financial Statements EX-99.2 4 non-reliancepressreleaseex.htm EXHIBIT 99.2 EXHIBIT 99.2 Apyx Medical Corporation to Restate Previously Issued Financial Statements CLEARWATER, FL - MARCH 16, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in th
March 16, 2020	EX-99.1	Apyx Medical Corporation Reports Fourth Quarter and Full Year of 2019 Preliminary Unaudited Financial Results and Introduces First Quarter of Fiscal Year 2020 Financial Outlook Advanced Energy Sales increase 58% year-over-year in Q4 and increase 73% EXHIBIT 99.1 Apyx Medical Corporation Reports Fourth Quarter and Full Year of 2019 Preliminary Unaudited Financial Results and Introduces First Quarter of Fiscal Year 2020 Financial Outlook Advanced Energy Sales increase 58% year-over-year in Q4 and increase 73% year-over-year in FY'19 CLEARWATER, FL — MARCH 16, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devi
March 16, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 March 16, 2020 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
March 16, 2020	EX-99.2	Apyx Medical Corporation to Restate Previously Issued Financial Statements EXHIBIT 99.2 Apyx Medical Corporation to Restate Previously Issued Financial Statements CLEARWATER, FL - MARCH 16, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced it will be
March 16, 2020	NT 10-K	BVX / Bovie Medical Corp. NT 10-K - - NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): xForm 10-K oForm 20-F o Form 11-K oForm 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: December 31, 2019 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on F
February 14, 2020	EX-1	Joint Filing Statement Pursuant to Rule 13d-1(k)(1) Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G Amendment No.
February 14, 2020	SC 13G/A	APYX / Apyx Medical Corporation / RTW INVESTMENTS, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 13, 2020	SC 13G/A	APYX / Apyx Medical Corporation / Archon Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
January 13, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) January 13, 2020 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati
January 13, 2020	EX-99.1	Apyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2019 Revenue Results Advanced Energy Sales of approximately $6.6 to $6.9 million in Q4, up 52% to 58% year-over-year EX-99.1 2 apyx20200113xex991pressre.htm EXHIBIT 99.1 EXHIBIT 99.1 Apyx Medical Corporation Reports Preliminary Full Year and Fourth Quarter 2019 Revenue Results Advanced Energy Sales of approximately $6.6 to $6.9 million in Q4, up 52% to 58% year-over-year CLEARWATER, FL - JANUARY 13, 2020 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the dev
January 9, 2020	SC 13G/A	APYX / Apyx Medical Corporation / VANDERFELT WILLIAM WEEKS - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* APYX MEDICAL CORPORATION (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03837C106 (CUSIP Number) December 31, 2019 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des
December 3, 2019	EX-99.1	Apyx Medical Corporation Announces Subject Enrollment Initiated in New Study Evaluating the Use of Renuvion® Technology in Dermal Resurfacing Procedures Apyx Medical Corporation Announces Subject Enrollment Initiated in New Study Evaluating the Use of Renuvion® Technology in Dermal Resurfacing Procedures CLEARWATER, FL - DECEMBER 3, 2019 - Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and as J-Plasma® in the hospital surgical market, announced today that it has initiated subject enrollment in a U.
December 3, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) December 3, 2019 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati
November 15, 2019	10-Q	BVX / Bovie Medical Corp. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPO
November 12, 2019	NT 10-Q	BVX / Bovie Medical Corp. NT 10-Q - - NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): oForm 10-K oForm 20-F o Form 11-K xForm 10-Q o Form 10-D o Form N-SAR o Form N-CSR For Period Ended: September 30, 2019 o Transition Report on Form 10-K o Transition Report on Form 20-F o Transition Report on Form 11-K o Transition Report on Form 10-Q o Transition Report on
November 12, 2019	EX-99.1	Apyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $6.1 million in Q3, up 104% year-over-year EXHIBIT 99.1 Apyx Medical Corporation Reports Third Quarter of 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $6.1 million in Q3, up 104% year-over-year CLEARWATER, FL — NOVEMBER 11, 2019 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion
November 12, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 November 11, 2019 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizat
October 15, 2019	EX-99.1	Apyx Medical Corporation Receives 510(k) Clearance for the Apyx Plasma/RF Handpiece EX-99.1 2 pressrelease2exhibit.htm EXHIBIT 99.1 Apyx Medical Corporation Receives 510(k) Clearance for the Apyx Plasma/RF Handpiece CLEARWATER, FL - OCTOBER 14, 2019 - Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic s
October 15, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 14, 2019 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati
October 15, 2019	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) October 14, 2019 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organizati
October 15, 2019	EX-99.1	Apyx Medical Corporation Announces Subject Enrollment Initiated in Study Evaluating the Use of Renuvion® Technology in Skin Laxity Procedures in the Neck and Submental Region EX-99.1 2 pressreleaseexhibit991.htm EXHIBIT 99.1 Apyx Medical Corporation Announces Subject Enrollment Initiated in Study Evaluating the Use of Renuvion® Technology in Skin Laxity Procedures in the Neck and Submental Region CLEARWATER, FL - OCTOBER 14, 2019 - Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and th
September 28, 2019	S-8	BVX / Bovie Medical Corp. S-8 - - S-8 S-8 1 apyxs-8x201909.htm S-8 As filed with the Securities and Exchange Commission on September 27, 2019 Registration No. 333- =========================================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 APYX MEDICAL CORPORATION (exact name of Regis
August 7, 2019	EX-99.1	Apyx Medical Corporation Reports Second Quarter and First Half of 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $5.3 million in Q2, up 69% year-over-year EXHIBIT 99.1 Apyx Medical Corporation Reports Second Quarter and First Half of 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $5.3 million in Q2, up 69% year-over-year CLEARWATER, FL — AUGUST 7, 2019 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold
August 7, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 7, 2019 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
August 7, 2019	EX-99.1	Apyx Medical Corporation Announces Appointment of Minnie Baylor-Henry to the Company’s Board of Directors Apyx Medical Corporation Announces Appointment of Minnie Baylor-Henry to the Company’s Board of Directors CLEARWATER, FL - AUGUST XX, 2019 - Apyx Medical Corporation, formerly Bovie Medical Corporation, (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of its Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that the Company has appointed Minnie Baylor-Henry to the Board of Directors, effective August 1, 2019.
August 7, 2019	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) August 1, 2019 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization
August 7, 2019	10-Q	BVX / Bovie Medical Corp. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATIO
June 21, 2019	DEF 14A	4.1 Apyx Medical Corporation 2019 Share Incentive Plan* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a–6(e)(2)) ý Defin
June 4, 2019	8-K	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 June 3, 2019 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its Charter) Delaware 12183 11-2644611 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.
June 4, 2019	EX-16.1	Letter from Frazier & Deeter, LLC Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Ladies and Gentlemen: We have read the statements made by Apyx Medical Corporation as filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K of Apyx Medical Corporation dated June 3, 2019. We agree with the statements concerning our Firm contained therein. Sincerely, /s/ Frazier & Deeter, LLC
May 31, 2019	SD	BVX / Bovie Medical Corp. SD - - SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 12183 11-2644611 (State or other jurisdiction of incorporation or organization) (Commission File Number) (IRS Employer Identification No.) 5115 Ulmerton Road Clearwater, Florida 33760 (Address of princ
May 8, 2019	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported) May 8, 2019 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 0-12183 11-2644611 (State or other jurisdiction of incorporation or organization) (
May 8, 2019	EX-99.1	Apyx Medical Corporation Reports First Quarter 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $4.4 million in Q1, up 66% year-over-year EXHIBIT 99.1 Apyx Medical Corporation Reports First Quarter 2019 Financial Results and Updates Fiscal Year 2019 Outlook Advanced Energy Sales of $4.4 million in Q1, up 66% year-over-year CLEARWATER, FL — MAY 8, 2019 - Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of J-Plasma®, a patented surgical product marketed and sold under th
May 8, 2019	10-Q	BVX / Bovie Medical Corp. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0-12183 APYX MEDICAL CORPORATI
April 26, 2019	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 April 26, 2019 Date of Report (Date of earliest event reported) APYX MEDICAL CORPORATION (Exact name of registrant as specified in its Charter) Delaware 12183 11-2644611 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.

APYX / Apyx Medical Corporation - Документы SEC, Годовой отчет, Доверенное заявление

Основная статистика

SEC Filings

SEC Filings (Chronological Order)

Other Listings